TIDMAVCT

RNS Number : 1783V

Avacta Group PLC

12 April 2021

12 April 2021

Avacta Group plc

("Avacta" or "the Group" or "the Company")

Issue of Equity

Avacta Group plc (AIM: AVCT), the developer of innovative cancer therapies and diagnostics based on its proprietary Affimer(R) and pre|CISION(TM) platforms, today announces that following the exercise of share options under an historic services agreement it has issued and allotted in total 20,689 new ordinary shares of 10 pence each in the Company ("Ordinary Shares").

Application will be made for the Ordinary Shares to be admitted to trading on AIM and dealings are expected to commence on 16 April 2021 ("Admission") . The Ordinary Shares will rank pari passu with the existing Ordinary Shares of the Company.

Following Admission, the Company's enlarged issued share capital will be 253,395,434 . This figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.

-Ends -

For further information from Avacta Group plc, please contact:

 
 Avacta Group plc                                                 Tel: +44 (0) 844 414 
  Alastair Smith, Chief Executive Officer                                         0452 
  Tony Gardiner, Chief Financial Officer                                www.avacta.com 
 finnCap Ltd (Nomad and Joint Broker)                             Tel: +44 (0) 207 220 
  Geoff Nash / Giles Rolls / Teddy Whiley                                         0500 
  - Corporate Finance                                                  www.finncap.com 
  Tim Redfern - ECM 
 
   Stifel Nicolaus Europe Limited (Joint                          Tel: +44 (0) 207 710 
   Broker)                                                                        7600 
 Nicholas Moore / Nick Adams / Fred Walsh                               www.stifel.com 
  / Ben Maddison 
  FTI Consulting (Financial                                            Tel: +44 (0) 203 727 1000 
   Media and IR) 
  Simon Conway / Stephanie Cuthbert                                   avacta@f ticonsulting .com 
 
 
   Zyme Communications (Trade and                             Tel: +44 (0)7787 502 947 
   Regional Media)                                katie.odgaard@zymecommunications.com 
   Katie Odgaard 
 
 
   About Avacta Group plc -   https://www.avacta.com 

Avacta Group is developing novel cancer immunotherapies and powerful diagnostics based on its two proprietary platforms - Affimer(R) biologics and pre|CISION(TM) tumour targeted chemotherapies.

The Affimer platform is an alternative to antibodies derived from a small human protein. Despite their shortcomings, antibodies currently dominate markets, such as diagnostics and therapeutics, worth in excess of $100bn. Affimer technology has been designed to address many of these negative performance issues, principally: the time taken to generate new antibodies and the reliance on an animal's immune response; poor specificity in many cases; their large size, complexity and high cost of manufacture.

Avacta's pre|CISION targeted chemotherapy platform releases active chemotherapy in the tumour, which limits the systemic exposure that causes damage to healthy tissues, and thereby improves the overall safety and therapeutic potential of these powerful anti-cancer treatments.

The Group comprises two divisions: The therapeutics development activities are based in Cambridge, UK and the Group is generating near-term revenues from Affimer reagents for diagnostics, bioprocessing and research, through a separate diagnostics business unit based in Wetherby, UK.

Avacta's Diagnostics Division works with partners world-wide to develop bespoke Affimer reagents for third party products. The Group is also developing an in-house pipeline of Affimer-based diagnostic assays including the AffiDX(R) SARS-CoV-2 Lateral Flow Rapid Antigen Test and AffiDX(R) BAMS(TM) SARS-CoV-2 Assay in partnership with Adeptrix Inc.

Avacta's Therapeutics Division is addressing a critical gap in current cancer treatment - the lack of a durable response to current immunotherapies experienced by most patients. By combining its two proprietary platforms the Group is building a wholly owned pipeline of novel cancer therapies deigned to be effective for all cancer patients. In 2021 Avacta will commence a phase 1 first-in-human, open label, dose-escalation and expansion study of AVA6000 Pro-doxorubicin, the Group's lead pre|CISION(TM) prodrug, in patients with locally advanced or metastatic selected solid tumours.

Avacta has established drug development partnerships with pharma and biotech, including a research collaboration with ModernaTX,Inc. (formerly Moderna Therapeutics Inc.), a multi-target deal with LG Chem worth up to $400m, a joint venture in South Korea with Daewoong Pharmaceutical focused on cell and gene therapies incorporating Affimer immune-modulators, a partnership with ADC Therapeutics to develop Affimer-drug conjugates and a collaboration with Point Biopharma to develop radiopharmaceuticals based on the pre|CISION(TM) platform. Avacta continues to actively seek to license its proprietary platforms in a range of therapeutic areas.

   To register for news alerts by email go to   www.avacta.com/investor-news-email-alerts 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

IOEUUUURAUUSAAR

(END) Dow Jones Newswires

April 12, 2021 08:30 ET (12:30 GMT)

Avacta (LSE:AVCT)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more Avacta Charts.
Avacta (LSE:AVCT)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Avacta Charts.